Evidence map›Paper›PMID 29940939›Full record

ArticleBMC infectious diseases2018

Seroprevalence and risk factors of recent infection with hepatitis E virus during an acute outbreak in an urban setting in Chad, 2017.

Larissa Vernier, Annick Lenglet, Boris M Hogema, Ali M Moussa, Cono Ariti, Simone Vollmer, Andrea Irwin, Prince Alfani, Sibylle Sang, Charity Kamau

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Hepatitis E vaccine-Illuminating the barriers to use.PLoS neglected tropical diseases · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Hepatitis E: What We Think We Know.Clinical liver disease · 2020
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Larissa VernierMédecins sans Frontières, Operational Center Amsterdam (OCA), Quartier Aeroport, A1, Rue 1039, Porte 405, BP30, N'Djamena, Chad.
Annick LengletMédecins sans Frontières, Operational Center Amsterdam (OCA), Plantage Middenlaan 14, 1018DD, Amsterdam, the Netherlands. annick.lenglet@amsterdam.msf.org.ORCID 0000-0003-2013-8405
Boris M HogemaSanquin Diagnostic Services, Department of Virology, Plesmanlaan 125, 1066 CX, Amsterdam, The Netherlands.
Ali M MoussaMinistry of Health, BP440, N'Djamena, Chad.
Cono AritiMedical Statistics, London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E7HT, UK.
Simone VollmerMédecins sans Frontières, Operational Center Amsterdam (OCA), Quartier Aeroport, A1, Rue 1039, Porte 405, BP30, N'Djamena, Chad.
Andrea IrwinMédecins sans Frontières, Operational Center Amsterdam (OCA), Quartier Aeroport, A1, Rue 1039, Porte 405, BP30, N'Djamena, Chad.
Prince AlfaniMédecins sans Frontières, Operational Center Amsterdam (OCA), Quartier Aeroport, A1, Rue 1039, Porte 405, BP30, N'Djamena, Chad.
Sibylle SangMédecins sans Frontières, Operational Center Amsterdam (OCA), Plantage Middenlaan 14, 1018DD, Amsterdam, the Netherlands.
Charity KamauMédecins sans Frontières, Operational Center Amsterdam (OCA), Plantage Middenlaan 14, 1018DD, Amsterdam, the Netherlands.
Médecins Sans Frontières · NLSanquin · NLUniversity of London · GBUniversity of N'Djamena · TD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFrom September 2016-April 2017, Am Timan, Chad, experienced a large HEV outbreak in an urban setting with a limited impact in terms of morbidity and mortality. To better understand HEV epidemiology in this context, we estimated the seroprevalence of anti-HEV antibodies (IgM and IgG) and assessed the risk factors for recent HEV infections (positive anti-HEV IgM) during this outbreak.

methodsA serological survey using simple random sampling was implemented in Am Timan at the tail-end of the outbreak (sample size aim = 384 household). Household members provided us with blood samples and household heads answered questions around water, sanitation and hygiene practices and animal ownership. Blood samples were tested for HEV IgG and IgM antibodies using Enzyme-Immune-Assay (EIA). We calculated weighted prevalence estimates and prevalence ratios (PRs) for possible risk factors for recent infection using multivariate Cox regression.

resultsWe included 241 households (1529 participants). IgM prevalence decreased with age: 12.6% (< 5 years) to 4.3% (> 15 years). IgG prevalence increased with age: 23.5% (< 5 years) to 75.9% (> 15 years). Risk factors for recent HEV infections included: sharing the sanitation facility with other HHs (PR 1.72; 95%CI: 1.08-2.73), not systematically using soap for HW (PR 1.85; 95%CI: 1.30-2.63) and having animals sleeping inside the compound (PR 1.69; 95%CI: 1.15-2.50).

conclusionsEvidence suggests that Am Timan was already highly endemic for HEV before the outbreak, potentially explaining the limited extent of the outbreak. Recent infection with HEV was linked to household level exposures. Future HEV outbreak response must include ensuring access to safe water, and reducing household level transmission through active hygiene and sanitation promotion activities.

Indexed as

AdolescentAdultChadChildChild, PreschoolDisease OutbreaksFemaleGenotypeHepatitis AntibodiesHepatitis EHepatitis E virusHumansImmunoglobulin GInfantInfant, NewbornMaleHepatitis AntibodiesImmunoglobulin GChadDisease outbreaksHepatitis E virusRisk factorsSeroepidemiologic studies

Identifiers

PMID29940939
PMCPMC6020170
OpenAlexW2811176155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.